Disc Medicine Inc
IRON85.120USD
+1.540+1.84%
Horário de mercado （ET）Cotações atrasadas em 15 min
2.98BValor de mercado
PerdaP/L TTM
Mais detalhes de Disc Medicine Inc Empresa
Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Informações de Disc Medicine Inc
Código da empresaIRON
Nome da EmpresaDisc Medicine Inc
Data de listagemAug 12, 2020
CEODr. John D. Quisel, J.D., Ph.D.
Número de funcionários84
Tipo de títulosOrdinary Share
Fim do ano fiscalAug 12
Endereço321 Arsenal Street, Suite 101
CidadeWATERTOWN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02472
Telefone16176749274
Sitehttps://www.discmedicine.com/
Código da empresaIRON
Data de listagemAug 12, 2020
CEODr. John D. Quisel, J.D., Ph.D.
Executivos da empresa Disc Medicine Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
+162.73%
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-91.33%
Mr. Jonathan Yu
Mr. Jonathan Yu
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Jean M. Franchi, CPA
Ms. Jean M. Franchi, CPA
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Dr. William Savage, M.D., Ph.D.
Dr. William Savage, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Mr. Kevin J. Bitterman, Ph.D.
Mr. Kevin J. Bitterman, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
+162.73%
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-91.33%
Mr. Jonathan Yu
Mr. Jonathan Yu
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 3 de set
Atualizado em: qua, 3 de set
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
8.17%
Access Industries, Inc.
7.46%
Atlas Venture
5.69%
BlackRock Institutional Trust Company, N.A.
4.54%
Frazier Life Sciences Management, L.P.
4.38%
Outro
69.76%
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
8.17%
Access Industries, Inc.
7.46%
Atlas Venture
5.69%
BlackRock Institutional Trust Company, N.A.
4.54%
Frazier Life Sciences Management, L.P.
4.38%
Outro
69.76%
Tipos de investidores
Investidores
Proporção
Investment Advisor
38.37%
Investment Advisor/Hedge Fund
18.33%
Hedge Fund
17.95%
Venture Capital
12.84%
Private Equity
9.90%
Corporation
8.10%
Research Firm
1.48%
Sovereign Wealth Fund
0.83%
Individual Investor
0.47%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
341
35.08M
92.93%
-3.22M
2025Q2
344
37.34M
107.82%
+1.72M
2025Q1
342
37.53M
108.38%
+1.77M
2024Q4
318
30.70M
90.70%
-5.11M
2024Q3
302
32.06M
106.93%
-4.30M
2024Q2
292
32.17M
107.84%
+2.52M
2024Q1
275
26.60M
108.28%
-1.06M
2023Q4
248
24.37M
101.48%
-1.80M
2023Q3
211
23.78M
99.79%
-259.52K
2023Q2
190
22.86M
100.53%
+3.93M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fidelity Management & Research Company LLC
3.08M
8.87%
+31.14K
+1.02%
Jun 30, 2025
Access Industries, Inc.
3.56M
10.24%
--
--
Feb 27, 2025
Atlas Venture
2.15M
6.18%
-235.47K
-9.88%
Aug 14, 2025
BlackRock Institutional Trust Company, N.A.
1.71M
4.93%
-38.49K
-2.20%
Jun 30, 2025
Frazier Life Sciences Management, L.P.
1.65M
4.76%
-100.00K
-5.70%
Jun 30, 2025
RA Capital Management, LP
1.58M
4.54%
--
--
Jun 30, 2025
Janus Henderson Investors
1.55M
4.47%
+130.70K
+9.18%
Jun 30, 2025
T. Rowe Price Associates, Inc.
1.49M
4.3%
+155.07K
+11.58%
Jun 30, 2025
The Vanguard Group, Inc.
1.39M
4%
+90.73K
+6.98%
Jun 30, 2025
Wellington Management Company, LLP
1.43M
4.12%
-911.41K
-38.89%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
ALPS Medical Breakthroughs ETF
1.37%
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
SPDR S&P Biotech ETF
0.63%
Direxion Daily S&P Biotech Bull 3X Shares
0.36%
JPMorgan Fundamental Data Science Small Core ETF
0.29%
ProShares Ultra Nasdaq Biotechnology
0.24%
Invesco Nasdaq Biotechnology ETF
0.23%
iShares Health Innovation Active ETF
0.17%
iShares Biotechnology ETF
0.14%
Fidelity Fundamental Small-Mid Cap ETF
0.13%
Ver Mais
ALPS Medical Breakthroughs ETF
Proporção1.37%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.9%
SPDR S&P Biotech ETF
Proporção0.63%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.36%
JPMorgan Fundamental Data Science Small Core ETF
Proporção0.29%
ProShares Ultra Nasdaq Biotechnology
Proporção0.24%
Invesco Nasdaq Biotechnology ETF
Proporção0.23%
iShares Health Innovation Active ETF
Proporção0.17%
iShares Biotechnology ETF
Proporção0.14%
Fidelity Fundamental Small-Mid Cap ETF
Proporção0.13%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Data
Tipo
Proporção
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
